Health
J&J COVID-19 vaccine is 72% effective in the U.S., and 66% overall in large trial – Reuters
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will…
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from…
-
Noosa News20 hours agoAnimal Welfare Notices issued to SA’s Andgar Piggery after 14 euthanased by RSPCA
-
General21 hours agoReport finds 2032 Brisbane Olympic and Paralympic Games could bring $70 billion in economic opportunities
-
Noosa News20 hours agoBrisbane 2032 could bring a $70 billion windfall: Deloitte
-
Business24 hours agoWhat ASX 200 investors just learned about the next RBA interest rate move